Abstract
Rationale
The antipsychotic pharmacological treatment effectiveness and side effects are at least partially driven by the genetic personal background.
Objectives
In the present study, 71 genetic variations located in 21 candidate genes were investigated as modulators of the haloperidol efficacy and side effects in a sample of 101 acutely ill psychotic patients.
Methods
Patients were assessed at days 0, 7, 14, 21, and 28 (Positive and Negative Syndrome Scale (PANSS) test) and days 1, 3, 7, 14, 21, and 28 (UKU, BAS, and ESRS tests). Haloperidol plasma levels were measured at the same timepoints.
Results
None of the 71 variations were associated with response to treatment or with incidence of side effects passed a multiple testing threshold. A marginal association was detected between two haplotypes within the signal transducer and activator of transcription 4 gene and PANSS positive and dopamine beta-hydroxylase with PANSS negative scores (p = 0.004 and p = 0.008, respectively).
Conclusions
In conclusion, no major association was observed between the investigated variations and the efficacy profile of haloperidol.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arranz MJ, de Leon J (2007) Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12:707–747
Arranz MJ, Kapur S (2008) Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 34:1130–1144
Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676
Chouinard G, Margolese HC (2005) Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 76:247–265
de Leon J (2009) The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res 59:81–89
Drago A, De Ronchi D, Serretti A (2007) Incomplete coverage of candidate genes: a poorly considered bias. Curr Genomics 7:476–483
Giegling I, Drago A, Schafer M, Moller HJ, Rujescu D, Serretti A (2010) Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J Psychiatr Res 44(8):487–492
Hanson DR, Gottesman II (2005) Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet 6:7
Holden RJ, Pakula IS (1995) Could the inflammatory cytokines cause schizophrenia? Aust N Z J Psychiatry 29:693–695
Jorgensen G (1966) Comparative pharmacogenetics of humans and mammals. II. Med Welt 2:84–91
Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276
Kim CH, Zabetian CP, Cubells JF, Cho S, Biaggioni I, Cohen BM, Robertson D, Kim KS (2002) Mutations in the dopamine beta-hydroxylase gene are associated with human norepinephrine deficiency. Am J Med Genet 108:140–147
Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, Woerner MG, Kane JM, Goldman D, Malhotra AK (2006) DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 163:529–531
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100
Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 14:143–149
Malhotra AK, Murphy GM Jr, Kennedy JL (2004) Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780–796
Molteni R, Calabrese F, Racagni G, Fumagalli F, Riva MA (2009) Antipsychotic drug actions on gene modulation and signaling mechanisms. Pharmacol Ther 124:74–85
Motulsky AG (1964) Pharmacogenetics. Prog Med Genet 23:49–74
Nawa H, Takei N (2006) Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 56:2–13
Nnadi CU, Malhotra AK (2007) Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. Curr Psychiatry Rep 9:313–318
Oken RJ, McGeer PL (1996) Schizophrenia, Alzheimer’s disease, and anti-inflammatory agents. Schizophr Bull 22:1–4
Roden DM, George AL Jr (2002) The genetic basis of variability in drug responses. Nat Rev Drug Discov 1:37–44
Ronaghi M (2003) Pyrosequencing for SNP genotyping. Methods Mol Biol 212:189–195
Schafer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B, Moller HJ (2001) Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 158:802–804
Serretti A, Drago A, De Ronchi D (2007) HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem 14:2053–2069
Sodhi MS, Arranz MJ, Curtis D, Ball DM, Sham P, Roberts GW, Price J, Collier DA, Kerwin RW (1995) Association between clozapine response and allelic variation in the 5-HT2C receptor gene. NeuroReport 7:169–172
Sullivan PF (2007) Spurious genetic associations. Biol Psychiatry 61:1121–1126
Templeman LA, Reynolds GP, Arranz B, San L (2005) Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 15:195–200
Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L (2005) Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 376:1–4
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Giegling, I., Drago, A., Schäfer, M. et al. Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment. Psychopharmacology 214, 719–728 (2011). https://doi.org/10.1007/s00213-010-2080-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-010-2080-8